Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by JayjayUSA12007on May 16, 2018 10:15pm

167 Views

Post# 28043182

RE:RE:RE:LES AFFAIRES: banque nationale - LENO

Thanks.
He used a combination of discounted cash-flow model and earnings multiplier model.
He probably added the results and divided by 2 to get the average.
The question is which multiplier he was using ? All the numbers are black and white (i.e. price, patients, percentage of revenues, number of shares...), but the multiplier is subject to bias.

Bullboard Posts

Invest wiser with BMO's InvestorLine Platform features